Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry

Arash Ghalyanchilangeroudi; Rima Morshed; Mohammad Zahed Abbasi; Hossein Hosseini

doi:doi:10.11648/j.ijast.20220602.11

| Peer-Reviewed

Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry

Arash Ghalyanchilangeroudi, Rima Morshed, Mohammad Zahed Abbasi, Hossein Hosseini

Published in International Journal of Animal Science and Technology (Volume 6, Issue 2)

Received: 14 March 2022 Accepted: 13 April 2022 Published: 22 April 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Marek's disease (MD) is a lymphoproliferative viral disease of chickens, controlled through vaccination since 1969. MD vaccines can protect chickens against tumor development. However, due to various factors, MD outbreaks have occurred in the Iranian vaccinated layer flocks recently. MD vaccines are different in replication ability and providing immunity. This study aimed to investigate the replication ability and compare the vaccine-take of MD Vaccines from two companies (A and B). One hundred eighty layer chickens were divided into six groups of 30 birds. All groups received the (Rispens CVI988 +HVT) vaccine in the hatchery except the control group. The groups included Company A (SC, one dose), Company A (IM, one dose), Company B (SC, one dose), Company B (IM, one dose), and Company B (SC, 1.5 doses). Feather follicles were collected individually from chicks on days 7, 14, and 21 after vaccination. After DNA extraction, specific real-time PCR for detecting Rispense and HVT strains has been run on the samples. Only 70% of the chicks in the groups vaccinated by vaccine from Company B (IM & SC, one dose & 1.5 doses) were positive for Rispens strain in the first sampling, whereas 90% of chicks vaccinated by vaccine from Company A (IM & SC) were positive on day 7. At 21 days' post-vaccination, just the chicks vaccinated by SC route from company B could not provide 100% take, and the positive rate was 90%. In the HVT strain evaluation, although the positive rate in the first week after vaccination was quite low, between 10-30%, all groups showed an acceptable positive rate (90-100%) 21 days' post-vaccination. This finding supports the vaccine failure due to different vaccines' abilities to produce early immunity in chicks before seven days of age which is crucial to protect them against MDV early exposure.

Published in	International Journal of Animal Science and Technology (Volume 6, Issue 2)
DOI	10.11648/j.ijast.20220602.11
Page(s)	30-34
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Marek’s Disease, Vaccination, HVT, Rispens, CVI988, Iran

References

[1]	Baigent, S. J, Smith, L. P, Currie, R. J, Nair, V. K. 2007. Correlation of Marek's disease herpesvirus vaccine virus genome load in feather tips with protection, using an experimental challenge model, Avian Pathology 36 (6): 467-474.
[2]	Cho, B, Balch, R, Hill, R. 1976. Marek's disease vaccine breaks: differences in viremia of vaccinated chickens between those with and without Marek's disease, Avian diseases 20 (3): 496-503.
[3]	Cortes, A. L, Montiel, E. R, Lemiere, S, Gimeno, I. M. 2011. Comparison of blood and feather pulp samples for the diagnosis of Marek's disease and for monitoring Marek's disease vaccination by real time-PCR. Avian diseases 55 (2): 302-310.
[4]	Gimeno, I. M, Cortes, A. L, Silva, R. 2008. Load of challenge Marek's disease virus DNA in blood as a criterion for early diagnosis of Marek's disease tumors. Avian diseases 52 (2): 203-208.
[5]	Gimeno, I. M, Dunn, J. R, Cortes A. L, El-Gohary, A. E -G. Silva, R. F. 2014. Detection and differentiation of CVI988 (Rispens vaccine) from other serotype 1 Marek's disease viruses, Avian diseases 58 (2): 232-243.
[6]	Hooft van Iddekinge, B. J. L, Stenzler, L, Schat, K, Boerrigter, H, Koch, G. 1999. Genome analysis of Marek's disease virus strain CVI-988: effect of cell culture passage on the inverted repeat regions. Avian diseases 43 (2): 182-188.
[7]	Lee, L. F., Kreager, K. S., Arango, J., Paraguassu, A. 2010. Comparative evaluation of vaccine efficacy of recombinant Marek's disease virus vaccine lacking Meq oncogene in commercial chickens. Vaccine 28 (5): 1294-9.
[8]	Oei, H, De Boer, G. 1986. Comparison of intramuscular and subcutaneous administration of Marek's disease vaccine, Avian Pathology 15 (3): L 569-579.
[9]	OIE Terrestrial Manual. 2018. Marek 's disease. Chapter 3.3.13: 952-963. https://www.oie.int/fileadmin/Home/fr/Health_standards/tahm/3.03.13_MAREK_DIS.pdf.
[10]	Okazaki, W, Purchase, H, Burmester, B. 1973. Vaccination against Marek's disease: possible causes of failure of herpesvirus of turkeys (strain FC126) to protect chickens against Marek's disease, American journal of veterinary research 34 (6): 813.
[11]	Madej, J. P., Woźniakowski, G., Gaweł, A. 2016. Morphology of immune organs after very virulent plus strain of Marek’s disease virus infection in vaccinated hens", Polish Journal of Veterinary Sciences 19 (2): 325-335.
[12]	Nair, V. 2005. Evolution of Marek's disease – A paradigm for incessant race between the pathogen and the host. The Veterinary Journal 170 (2): 175-183.
[13]	Ralapanawe, S, Renz, K, Burgess, S, Walkden-Brown, S. W. 2016. Field studies of the detection, persistence and spread of the Rispens CVI988 vaccine virus and the extent of co-infection with Marek's disease virus, Australian veterinary journal 94 (9): 329-337.
[14]	Ralapanawe, S, Walkden-Brown, S. W, Renz, K. G, Islam, A. F. 2016. Protection provided by Rispens CVI988 vaccine against Marek's disease virus isolates of different pathotypes and early prediction of vaccine take and MD outcome. Avian Pathology 45 (1): 26-37.
[15]	Rispens, B. H, van Vloten, H, Mastenbroek, N, Maas, H. J, Schat, K. A. 1972. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian diseases 16 (1): 108-125.
[16]	Witter, R, Lee, L, Fadly, A. 1995. Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek's disease virus. Avian diseases 39 (2): 269-284.

Cite This Article

Plain Text BibTeX RIS

APA Style

Arash Ghalyanchilangeroudi, Rima Morshed, Mohammad Zahed Abbasi, Hossein Hosseini. (2022). Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry. International Journal of Animal Science and Technology, 6(2), 30-34. https://doi.org/10.11648/j.ijast.20220602.11

Copy | Download

ACS Style

Arash Ghalyanchilangeroudi; Rima Morshed; Mohammad Zahed Abbasi; Hossein Hosseini. Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry. Int. J. Anim. Sci. Technol. 2022, 6(2), 30-34. doi: 10.11648/j.ijast.20220602.11

Copy | Download

AMA Style

Arash Ghalyanchilangeroudi, Rima Morshed, Mohammad Zahed Abbasi, Hossein Hosseini. Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry. Int J Anim Sci Technol. 2022;6(2):30-34. doi: 10.11648/j.ijast.20220602.11

Copy | Download

@article{10.11648/j.ijast.20220602.11,
  author = {Arash Ghalyanchilangeroudi and Rima Morshed and Mohammad Zahed Abbasi and Hossein Hosseini},
  title = {Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry},
  journal = {International Journal of Animal Science and Technology},
  volume = {6},
  number = {2},
  pages = {30-34},
  doi = {10.11648/j.ijast.20220602.11},
  url = {https://doi.org/10.11648/j.ijast.20220602.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijast.20220602.11},
  abstract = {Marek's disease (MD) is a lymphoproliferative viral disease of chickens, controlled through vaccination since 1969. MD vaccines can protect chickens against tumor development. However, due to various factors, MD outbreaks have occurred in the Iranian vaccinated layer flocks recently. MD vaccines are different in replication ability and providing immunity. This study aimed to investigate the replication ability and compare the vaccine-take of MD Vaccines from two companies (A and B). One hundred eighty layer chickens were divided into six groups of 30 birds. All groups received the (Rispens CVI988 +HVT) vaccine in the hatchery except the control group. The groups included Company A (SC, one dose), Company A (IM, one dose), Company B (SC, one dose), Company B (IM, one dose), and Company B (SC, 1.5 doses). Feather follicles were collected individually from chicks on days 7, 14, and 21 after vaccination. After DNA extraction, specific real-time PCR for detecting Rispense and HVT strains has been run on the samples. Only 70% of the chicks in the groups vaccinated by vaccine from Company B (IM & SC, one dose & 1.5 doses) were positive for Rispens strain in the first sampling, whereas 90% of chicks vaccinated by vaccine from Company A (IM & SC) were positive on day 7. At 21 days' post-vaccination, just the chicks vaccinated by SC route from company B could not provide 100% take, and the positive rate was 90%. In the HVT strain evaluation, although the positive rate in the first week after vaccination was quite low, between 10-30%, all groups showed an acceptable positive rate (90-100%) 21 days' post-vaccination. This finding supports the vaccine failure due to different vaccines' abilities to produce early immunity in chicks before seven days of age which is crucial to protect them against MDV early exposure.},
 year = {2022}
}

Copy | Download

TY - JOUR
T1 - Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry
AU - Arash Ghalyanchilangeroudi
AU - Rima Morshed
AU - Mohammad Zahed Abbasi
AU - Hossein Hosseini
Y1 - 2022/04/22
PY - 2022
N1 - https://doi.org/10.11648/j.ijast.20220602.11
DO - 10.11648/j.ijast.20220602.11
T2 - International Journal of Animal Science and Technology
JF - International Journal of Animal Science and Technology
JO - International Journal of Animal Science and Technology
SP - 30
EP - 34
PB - Science Publishing Group
SN - 2640-1312
UR - https://doi.org/10.11648/j.ijast.20220602.11
AB - Marek's disease (MD) is a lymphoproliferative viral disease of chickens, controlled through vaccination since 1969. MD vaccines can protect chickens against tumor development. However, due to various factors, MD outbreaks have occurred in the Iranian vaccinated layer flocks recently. MD vaccines are different in replication ability and providing immunity. This study aimed to investigate the replication ability and compare the vaccine-take of MD Vaccines from two companies (A and B). One hundred eighty layer chickens were divided into six groups of 30 birds. All groups received the (Rispens CVI988 +HVT) vaccine in the hatchery except the control group. The groups included Company A (SC, one dose), Company A (IM, one dose), Company B (SC, one dose), Company B (IM, one dose), and Company B (SC, 1.5 doses). Feather follicles were collected individually from chicks on days 7, 14, and 21 after vaccination. After DNA extraction, specific real-time PCR for detecting Rispense and HVT strains has been run on the samples. Only 70% of the chicks in the groups vaccinated by vaccine from Company B (IM & SC, one dose & 1.5 doses) were positive for Rispens strain in the first sampling, whereas 90% of chicks vaccinated by vaccine from Company A (IM & SC) were positive on day 7. At 21 days' post-vaccination, just the chicks vaccinated by SC route from company B could not provide 100% take, and the positive rate was 90%. In the HVT strain evaluation, although the positive rate in the first week after vaccination was quite low, between 10-30%, all groups showed an acceptable positive rate (90-100%) 21 days' post-vaccination. This finding supports the vaccine failure due to different vaccines' abilities to produce early immunity in chicks before seven days of age which is crucial to protect them against MDV early exposure.
VL - 6
IS - 2
ER -

Copy | Download

Author Information

Arash Ghalyanchilangeroudi

Department of Microbiology and Immunology, University of Tehran, Faculty of Veterinary Medicine, Tehran, Iran
Rima Morshed

Department of Basic Sciences, Faculty of Encyclopedia, Institute for Humanities and Cultural Studies, Tehran, Iran
Mohammad Zahed Abbasi

Toyoor Barekat, Tehran, Iran
Hossein Hosseini

Department of Clinical Sciences, Faculty of Veterinary Medicine, Karaj Branch, Islamic Azad University, Alborz, Iran

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Arash Ghalyanchilangeroudi, Rima Morshed, Mohammad Zahed Abbasi, Hossein Hosseini. (2022). Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry. International Journal of Animal Science and Technology, 6(2), 30-34. https://doi.org/10.11648/j.ijast.20220602.11

Copy | Download

ACS Style

Arash Ghalyanchilangeroudi; Rima Morshed; Mohammad Zahed Abbasi; Hossein Hosseini. Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry. Int. J. Anim. Sci. Technol. 2022, 6(2), 30-34. doi: 10.11648/j.ijast.20220602.11

Copy | Download

AMA Style

Arash Ghalyanchilangeroudi, Rima Morshed, Mohammad Zahed Abbasi, Hossein Hosseini. Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry. Int J Anim Sci Technol. 2022;6(2):30-34. doi: 10.11648/j.ijast.20220602.11

Copy | Download

@article{10.11648/j.ijast.20220602.11,
  author = {Arash Ghalyanchilangeroudi and Rima Morshed and Mohammad Zahed Abbasi and Hossein Hosseini},
  title = {Comparative Effectiveness of MD Bivalent Vaccines Using in Iranian Poultry Industry},
  journal = {International Journal of Animal Science and Technology},
  volume = {6},
  number = {2},
  pages = {30-34},
  doi = {10.11648/j.ijast.20220602.11},
  url = {https://doi.org/10.11648/j.ijast.20220602.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijast.20220602.11},
  abstract = {Marek's disease (MD) is a lymphoproliferative viral disease of chickens, controlled through vaccination since 1969. MD vaccines can protect chickens against tumor development. However, due to various factors, MD outbreaks have occurred in the Iranian vaccinated layer flocks recently. MD vaccines are different in replication ability and providing immunity. This study aimed to investigate the replication ability and compare the vaccine-take of MD Vaccines from two companies (A and B). One hundred eighty layer chickens were divided into six groups of 30 birds. All groups received the (Rispens CVI988 +HVT) vaccine in the hatchery except the control group. The groups included Company A (SC, one dose), Company A (IM, one dose), Company B (SC, one dose), Company B (IM, one dose), and Company B (SC, 1.5 doses). Feather follicles were collected individually from chicks on days 7, 14, and 21 after vaccination. After DNA extraction, specific real-time PCR for detecting Rispense and HVT strains has been run on the samples. Only 70% of the chicks in the groups vaccinated by vaccine from Company B (IM & SC, one dose & 1.5 doses) were positive for Rispens strain in the first sampling, whereas 90% of chicks vaccinated by vaccine from Company A (IM & SC) were positive on day 7. At 21 days' post-vaccination, just the chicks vaccinated by SC route from company B could not provide 100% take, and the positive rate was 90%. In the HVT strain evaluation, although the positive rate in the first week after vaccination was quite low, between 10-30%, all groups showed an acceptable positive rate (90-100%) 21 days' post-vaccination. This finding supports the vaccine failure due to different vaccines' abilities to produce early immunity in chicks before seven days of age which is crucial to protect them against MDV early exposure.},
 year = {2022}
}

Copy | Download